BioMotiv
Accelerating Breakthrough Discoveries into Medicines

News

News

Orca Pharmaceuticals Achieves Development Milestone and Secures Additional Funding

OXFORD, UK – April 28, 2014

Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project.

Click here to read more